Watch our 2023 retrospective video
IHU ICAN wishes you all the best
In 2023, our teams remained 100% mobilized in the fight against cardiometabolic diseases, the 1st cause of death worldwide and a major cause of death in France.
Watch our video retrospective of the year’s highlights.
Thank you to our 53 employees, 168 physicians, 221 researchers, as well as to our founders, partners, patrons and donors for their precious support throughout the year.
In 2024, let’s continue to innovate together to accelerate progress against cardiometabolic diseases. Happy New Year!
Clarivate 2023 ranking: 2 ICAN researchers among the most cited in the world!
Clarivate 2023 ranking: 2 ICAN researchers among the most cited in the world!
Clarivate’s “Highly Cited Researchers” ranking highlights the most influential researchers worldwide, with highly cited scientific publications over the last decade. It includes the top 1% of the world’s most cited researchers.
Our warmest congratulations go to Prof. Vlad Ratziu and Prof. Alain Combes, members of the ICAN IHU community, who feature in this 2023 ranking!
-
Prof. Vlad Ratziu (Gastroenterology and hepatology)
Prof. Ratziu’s research focuses on metabolic liver diseases, mainly metabolic steatosis (fatty liver).
He has taken part in therapeutic trials on metabolic steatohepatitis conducted with the ICAN IHU and AP-HP, and has published over 300 articles in numerous international journals.
Prof. Ratziu coordinated the Fatty Liver Inhibition of Progression (FLIP) consortium, which aimed to study both the mechanisms of liver disease progression in metabolic steatosis and therapeutic interventions, based on one of the largest patient cohorts in Europe.
He is co-editor of the Journal of Hepatology, the official journal of the European Association of Liver Studies (EASL).
-
Prof. Alain Combes (Intensive care medicine)
Prof. Alain Combes’ research focuses on the care of critically ill cardiac patients, mechanical circulatory assistance and extracorporeal membrane oxygenation, rescue therapies for severe respiratory failure, and infections in critically ill patients.
Professor Combes is a member of the European Society of Intensive Care Medicine (ESICM), the American Thoracic Society (ATS), the European Society of Cardiology (ESC), the Board of Directors of the Association for Acute Cardiovascular Care (ESC-ACVC), the Extracorporeal Life Support Organization (ELSO), where he is former Chairman of EURO-ELSO, the International ECMO Network (ECMONet) and the French Resuscitation Society (SRLF).
Prof. Combes is Deputy Editor-in-Chief of Intensive Care Medicine.
IHU ICAN launches its barometer on cardiometabolic diseases with IFOP
Cardio-metabolic diseases: we’re all concerned!
To better inform and raise public awareness of one of the major causes of death in France, the IHU ICAN is launching its cardiometabolic barometer (IFOP / IHU ICAN study – September 2023), drawing on its extensive expertise in research and the fight against cardiometabolic diseases.
- What do the French know about cardiometabolism?
- How do they view these pathologies?
- Are they informed about causes and risk factors?
A veritable public health scourge, cardiometabolic diseases have been steadily on the rise in recent years. Today, they represent a major cause of death in France and the 1st cause of death worldwide (source: CépiDc/Inserm).
They include many diseases such as diabetes, obesity, cardiovascular disease (hypertension, thrombosis, cardiomyopathy, stroke, heart failure), liver disease (including hepatic metabolic steatosis or fatty liver disease), and hypercholesterolemia.
How these chronic diseases work is still too little known to the general public, as cardiometabolism is an emerging discipline that requires a high level of expertise. cutting-edge scientific and medical research to understand these complex, interconnected pathologies, linked to an imbalance in the individual’s metabolism and/or to genetic factors. They are very common and often diagnosed too late, as they develop silently in the body.
Yet cardiometabolic diseases concern us all.
A few figures (in France):
- Cardiovascular diseases: 5.3 million sufferers, more than 140,000 deaths per year
- Diabetes: 4 million people treated, 35,000 diabetes-related deaths
- Obesity: 17% of adults are obese, 47% overweight
- Hepatic metabolic steatosis (NASH): 18% of the population affected, almost 24% in 2030 (IHU ICAN estimate)
Sources : ameli, Santé publique France
Cardiometabolic diseases, a scourge still too little known
The first lesson to be learned from this study, cardiometabolic diseases are poorly identified by the French: only 38% have heard of them and 10% see exactly what it’s all about. Young women and donors to medical research – two audiences traditionally more aware of health issues – are slightly more likely to declare that they know about pathologies (45% and 55%).
The 38% of French people who say they know about these diseases have only a partial knowledge of them. If they rightly identify heart failure (85%), hypertension (76%) and stroke (67%) as diseases of the cardiometabolic system, they are less than 1 in 2 know that obesity (49%), hypercholesterolemia (47%) and diabetes (37%) also belong to this family of diseases. Non-alcoholic hepatic steatosis (20%) and cirrhosis (12%) are even less closely related to this family.
As a corollary to this poor understanding of cardiometabolic diseases, their contribution to deaths in France is underestimated: 15% of French people declare it as the main cause of death in France, whereas it is one of the main causes after cancer, and the 1st cause of death worldwide.
Cardiometabolic diseases perceived as serious and on the rise
After explaining to respondents what cardiometabolic diseases are, 82% of them agreed that they are serious pathologies, 73% that they have increased over the last ten years, and 73% that they are widespread in the French population. On the other hand, the chronic nature of these pathologies seems to be largely unknown, with 57% of those surveyed explaining that they can now be cured.
It’s also worth noting that 1 in 2 French people believe that cardiometabolic diseases are primarily a matter of individual responsibility (50%), a result that goes hand in hand with the fact that they are perceived as being caused solely by lifestyle.
Well-identified preventive measures and risk factors
Another finding of the study is that cardiometabolic diseases are widely perceived by the French as being caused by lifestyle, with this cause being cited first (51%), far ahead of genetic predisposition (13%) or environmental factors such as pollution (6%).
As a corollary to this, the French believe that public authorities should above all fight against cardiometabolic diseases through campaigns to raise public awareness of lifestyle changes (36%). Conversely, only 15% mention scientific research and 12% the improvement of diagnostic tools, which are essential levers in the knowledge and fight against these diseases.
The French identify preventive health and diet measures fairly well: they believe that a balanced diet (94%), regular physical activity (93%), not smoking (92%) and not drinking too much alcohol (88%) are effective in preventing the onset of cardiometabolic diseases.
They also largely agree on the risk factors, citing being overweight (87%), being a smoker (86%), having a diet rich in fat, salt and sugar (85%) or a stressful lifestyle (82%).
More French people fear cardiovascular disease
The results of the study also show that judgments about the various cardiometabolic pathologies are ambivalent, probably because representations diverge according to the type of disease.
Cardiovascular diseases are now better identified as diseases of the cardiometabolic system, and give rise to a great deal of concern. This type of disease is by far the most worrying (50%), far ahead of hypertension (14%), diabetes (16%), obesity (11%), non-alcoholic fatty liver disease (6%) or hypercholesterolemia (3%).
As a corollary to this, the French feel that these are the diseases that should receive priority attention from the public authorities (46%), ahead of obesity (26%), diabetes (15%), rare metabolic diseases (7%), hypercholesterolemia (3%) and non-alcoholic fatty liver disease (3%).
A lack of information about cardiometabolic diseases
Just over a third of French people say they have already been informed about cardiometabolic diseases (37%). In detail, slightly more people over 65 (42%), wealthier people (48%) and donors to medical research (50%) say they have been informed.
Doctors are the main source of information about these diseases (57%), ahead of family and friends (37%), the media (29%) and government communication campaigns.
Who we are?
Created in 2011, IHU ICAN is a scientific cooperation foundation whose main objective is to develop tomorrow’s medicine to combat cardiometabolic diseases. Located in the heart of Europe’s largest public hospital, At the Pitié-Salpêtrière Hospital, the ICAN HCI draws on the expertise of its scientific community. (168 doctors, 261 researchers) and its 3 founders to carry out its missions: AP-HP (Assistance publique – Hôpitaux de Paris), Inserm (Institut national de la santé et de la recherche médicale) and Sorbonne University.
Any questions? Contact us:
- Francine TROCME
- Director of Communications and Patronage – IHU ICAN
- 06 81 64 97 88
- f.trocme@ihuican.org
Meeting of the IHU ICAN International Scientific Council: what are the major scientific orientations?
Meeting of the International Scientific Council of the IHU ICAN :
what are the major scientific orientations?
On September 25 and 26, 2023, IHU ICAN was pleased to welcome the members of its International Scientific Advisory Board to discuss the Foundation’s major scientific orientations in the fight against cardiometabolic diseases (obesity, diabetes, liver disease, heart and vessel disease, etc.).
The visit was punctuated by a cocktail in the heart of a unique place: the Saint-Louis de la Salpêtrière chapel, built in 1670 as part of the Pitié-Salpêtrière hospital.
The IHU ICAN would like to thank all the participants for their commitment and the quality of the discussions, as well as the AP-HP for making this wonderful event possible!
Strategic priorities of IHU ICAN, a benchmark scientific foundation in cardiometabolism
Stéphane Hatem, Director of the ICAN IHU, spoke about the ICAN IHU’s strategic priorities in the fight against cardiometabolic diseases, the leading cause of chronic illness and death in France.
- How can we better understand and decipher the dialogue between organs, particularly between the heart and the liver?
- What is the link between environmental and genomic factors? Rare monogenic cardiometabolic diseases with polymorphisms
- How can new biomarkers be used to develop precision medicine for the benefit of patients?
- How can we meet the challenge of generating and structuring high-quality healthcare data to accelerate medical and scientific research?
“IHU ICAN must fulfill its role as a partner and lever for a broader scientific and medical community in the field of cardiometabolism. Our foundation (set up by AP-HP, Inserm and Sorbonne Université) offers a full range of services and cutting-edge expertise, positioning members of its community at the forefront of major academic and industrial projects.
The integration of healthcare data into research, new interfaces for metabolic diseases, and the discovery of new biomarkers, particularly imaging biomarkers, are all challenges that perfectly illustrate the 2025/2030 orientations and ambitions for developing precision medicine for cardiometabolic diseases”.
Major scientific and medical research projects presented
Researchers and physicians from the IHU community then presented the major research projects currently underway, which represent encouraging advances in our understanding of cardiometabolic diseases and in tomorrow’s medicine, in the service of patients.
This SAB meeting was also an opportunity to welcome high-level personalities who were able to provide an expert view of the ICAN IHU presentations and make valuable recommendations:
- Pr Catherine Boileau, pharmacist-biologist specializing in genetics, Director of several research units, member of the ICAN IHU Administrative Committee,
- Pr Michel Komajda, Member of the French Academy of Medicine, Former Director of the Pitié-Salpêtrière Heart Institute, Former President of the European Society of Cardiology and President of the Heart & Research Foundation,
- Philip Janiak, Director of biotech Corteria Pharmaceuticals, former R&D Director of Sanofi’s Cardiometabolic Department, and member of the ICAN HCI Administrative Committee.
The heart-liver interface: a promising area of research
- Liver, the metabolic hub for cardiometabolic diseases – Pr Vlad Ratziu
- New mediators released by diseased liver – Pascal Ferré
- Necroptosis and MLD – Jérémie Gautheron
Adipose tissue, a central interface for cardiometabolic diseases
- Adipose tissue and heart : EAT and AF – Pr Stéphane Hatem
- Lipodystrophy from patient cohort to adipose tissue biology – Pr Corinne Vigouroux
Microbiota and cardiometabolic diseases
- Metabolic dysbiosis associated with obesity and CMD and interventionalstrategies : FMT to improve T2D control – Pr Judith Aron-Wisnewsky
From rare mutations to risk factors for cardiometabolic diseases
- Twin technology and the prediction of CV risk – Dr Antonio Gallo
- From rare familial forms of cardiomyopathy to common heart failure – Pr Philippe Charron
- Imprinting disease – Pr Irène Netchine
Accelerating the transfer of research into patient care
- New care pathways – Dr Raluca Pais
- Making the best out of patient cohorts (structuring a cohort strategy as atool for research and partnerships) – Stéphane Commans
Emerging talent, young researchers
- The biology of fatty atria – Nadine Suffee
- Metabolic biomarker and heart transplantation – Khaoula Bouazizi-Verdier
Creating links between basic and clinical research, and accelerating the transfer of research to patient care
- Maestria Demonstrator : AI tools for research – Maharajah Ponnaiah
- What can we expect form the reprogramming of Ips to study cardiometabolicdisease – Eric Villard
- Tools to promote emerging Scientific approaches – Pr Stéphane Hatem
Patient application: new imaging biomarkers for cardiometabolic diseases
- Cardio metabolic and liver imaging in the general population – Pr Alban Redheuil
- Technical developments in Cardiovascular MRI – Nadjia Kachenoura
- The new frontiers of the echocardiography – Dr Laurie Soulat Dufour
Composition and role of the International Scientific Council
Our International Scientific Advisory Board (SAB) is a strategic governance body made up of external personalities highly recognized by the international scientific community in the field of cardiometabolism and nutrition.
Its role is to evaluate the scientific strategy of the IHU ICAN and to make recommendations on the scientific orientations and the scientific and medical teams working within the scope of the IHU ICAN.
Members of the IHU ICAN Scientific Committee:
- Pr André CARPENTIER, Director of the “Diabetes, obesity and cardiovascular complications” key research area, Faculty of Medicine and Health Sciences at the Université de Sherbrooke, Canada
- Pr Michaël RODEN, Professor of Endocrinology and Metabolic Diseases, University Hospital of Düsseldorf, Germany
- Pr Karin SIPIDO, Chair of the SAB, Professor of Medicine and Head of Experimental Cardiology, University of Louvain, Belgium
- Pr Rozemarijn VLIEGENTHART, Radiologist and Professor of Cardiothoracic Imaging, University Medical Center Groningen, Netherlands
- Pr Arnold VON ECKARDSTEIN, Professor of Clinical Biochemistry, Laboratory Medicine and Pathology, University Centre for Laboratory, Medicine and Pathology (UZL), Switzerland
Review of the IHU France alliance white paper
A look back at the IHU France alliance white paper!
With 9.1% of its GDP allocated to healthcare, France attaches major importance to the care of its population and to medical and scientific research. 10 years after the creation of the IHU (University Hospital Institutes) by the French government, this agile and innovative structure has proved its flexibility, responsiveness and ability to innovate in the face of major public health challenges (health crisis, vaccination, gene therapy, e-health…).
In the healthcare sector, France now has all the resources it needs to be a pioneer in innovation. To pool this know-how, the 6 IHUs (FORESIGHT, ICAN, ICM, IMAGINE, LIRYC and IHU Strasbourg) are working together within the Alliance IHU France to improve their model, in the firm belief that it will have a major impact on the general population and on tomorrow’s medicine.
The result of this collaboration is the Alliance IHU France’s 1st white paper (February 2022), which sets out the ideas and avenues for development designed to perpetuate this model and boost the performance of existing and future IHUs.
Alliance IHU France: economic development valued at 1 billion euros
In 10 years :
- 18,000 scientific publications,
- 1,000 clinical trials,
- 320 patents filed,
- 450 doctoral students trained,
- 45 start-ups created,
- And an estimated 1 billion euros worth of economic activity.
“As part of the trajectory announced by the Innovation Santé 2030 plan, we are convinced that our alliance will contribute to making France a champion of innovation in healthcare in Europe by 2030,” explain the directors of Alliance IHU France.
10 years on: the effectiveness of the IHU model demonstrated
In 2012, the French government created the IHU (University Hospital Institutes) to develop medical innovation in France in major public health fields. This unique model combines fundamental and clinical research, training and commercialization through public/private partnerships, with the aim of developing tomorrow’s medicine for patients and healthcare operators, while at the same time developing this French industrial sector.
10 years on, the IHU model has proved its effectiveness, and the 3rd call for IHU projects, the winners of which will be announced shortly, is a further illustration of the positive results of the first two waves. Three successive Presidents of the Republic (2010-2023), from different political backgrounds, share the conviction that IHUs represent a model conducive to the emergence of major new discoveries for the benefit of the general population.
“Efficient coordinators of translational research and innovation, federators of public and private sectors, integrators of care and research, the IHUs are an essential part of the French healthcare innovation ecosystem,” explain the directors of Alliance IHU France. “They must provide :
- Ensure regular, decompartmentalized funding to encourage performance, and a single mandate to promote agility and responsiveness in the face of opportunities,
- Position themselves as effective coordinators of translational research and innovation, and move beyond site policy to network organization,
- To be pioneers in the field of creation and privileged grounds for experimentation,
- Be guarantors and promoters or co-promoters of clinical trials to elevate France internationally.”
The goal: to make France the 1st European nation in healthcare innovation and sovereignty
In February 2022, the Alliance IHU France published a white paper setting out a series of proposals for the sustainable development of the model:
- ACCELERATE and DE-RISK the transfer of innovations to patients, with the support of IHUs
- Proposal No. 1: Boost start-ups by facilitating the acquisition of equity stakes by the IHU.
- Proposal No. 2: Speed up negotiations with private-sector partners by giving the single mandate its full potential
- STRENGTHEN the role of HCIs as third places for experimentation and international appeal
- Proposal no. 3: Share the successes and lessons learned from HCIs for the benefit of national innovation
- Proposal 4: Position the IHU as a preferred site for experimentation in digital health, at the interface between healthcare and research.
- Proposal 5: Encourage the promotion of clinical trials by all UHIs, in conjunction with university hospitals and research organizations.
- To firmly establish the IHU in the French research and innovation landscape.
- Proposal No. 7: Provide long-term funding for HCIs through a base grant.
- Proposal No. 8: Enable IHUs to apply to calls for projects in their own name
With the help of the IHU, France has the capacity to meet international requirements and remain as reactive as it is competitive, so as to be well placed in the race for innovation in healthcare, already led by many countries.
Pictures ©Alkama.
In 2023, we continue our commitment! Discover our wishes on video
Happy New Year 2023!
In 2023, the entire community will continue its daily commitment to accelerate the progress of research and develop the medicine of tomorrow in cardiometabolism, in order to improve patient care.
We would like to thank all the people involved for the good realization of the scientific and medical projects of the IHU ICAN.
Thank you to our 53 employees, 168 physicians, 221 researchers, as well as to our founders, partners, patrons and donors for their precious support throughout the year.
Heroes' Run 2022 : our commitment to fighting heart failure
Heroes’ Run 2022 : our commitment to fighting heart failure
On June 19, the IHU ICAN participated in the “Heroes’ Run ” 2022 (“Course des Héros” in French), an associative and sporting event that allows people to collect donations to support the cause of their choice: disability, education, rare diseases, precariousness etc.
Our teams have chosen to support the fight against cardiovascular disease, the 1rst cause of death in the world after cancer.
IHU ICAN would like to warmly thank the generous donors who made it possible to collect a total of €5,865in donationsduring this event!
Our collectors thank you!
Thanks to your support, our 12 collectors from the IHU ICAN got together on Sunday, June 19 to take the start of the Heroes’ Run and spread the word about our cause during this festive and friendly event at the Domaine National de Saint-Cloud (92).
Over a distance of 6km or 10km, walking or running, the event allows everyone to commit to a cause that is important to them, regardless of their level of sport.
What is the UTHop’AI / RobEduc project?
The announcement of a heart failure diagnosis is an upheaval for patients. During his hospitalization, the patient will meet with multiple stakeholders to explain the new lifestyle habits to be applied upon his return home, but the dedicated time is often short and the repetition of key messages is important.
This project aims to raise awareness of therapeutic education for patients hospitalized for heart failure via a humanoid robot and artificial intelligence. This robot will complement the current inpatient care, in order to explain these new habits to patients.
Initiated at the request of the nursing staff, the project is led by Prof. Richard Isnard, Dr. Françoise Pousse and Dr. Lise Legrand of the cardiology department of the Pitié-Salpêtrière hospital (Paris 13th).
What will the collected donations be used for?
All the donations collected will help improve the care of heart failure patients by directly supporting the UTHop’IA / RobEduc project.
These donations will now be allocated to the engineering phase for the development of the robot’s mobility: electronic components, autonomous movement of the robot in the hospital (visits to patients’ rooms, opening of doors, etc.).
The next step will be the interaction of the robot with the patients.
Your donations are essential to support medical research on cardiometabolic diseases (obesity, diabetes, vascular and heart disease, etc.) alongside the IHU ICAN.
IHU ICAN creates a new platform entirely dedicated to the processing and analysis of health data: ICAN I/O
IHU ICAN creates a new platform entirely dedicated to the processing and analysis of health data: ICAN I/O
Identification of disease risk factors, assistance with diagnosis, choice and monitoring of treatment effectiveness or monitoring of patient trajectories… Today, data is generated massively in many scientific and medical fields. These data are grouped under the name “Big Data”. With Big Data, mathematical modelling, statistics and IT are becoming essential tools for managing and analyzing this massive information. The resulting new information profoundly transforms our approach to physiopathology and the underlying biological mechanisms. To meet the new challenge of Big Data, the IHU ICAN has created a dedicated platform: ICAN Intelligence and Omics (I/O).
The expertise of the ICAN Intelligence and Omics (I/O) platform brings together the three essential bricks for carrying out projects around Big Data in health: 1- Data governance 2- Data collection and data management 3- Analysis and integration of multi-omics and clinical data.
The creation of this new platform is thus an answer to the evolution of modern technologies and the use of robust algorithms to meet the needs of researchers through a collaborative and holistic approach integrating multi-omics technologies and statistical analysis. ICAN Intelligence and Omics (I/O) provides its expertise to structure, collect and manage the large amount of data generated within the framework of research projects. Extraction, analysis and large-scale processing of unstructured, heterogeneous and often compartmentalized data from different stakeholders in research projects are part of the expertise of the ICAN Intelligence and Omics platform. The use of data, their circulation, processing, sharing, induces major challenges that the IHU ICAN tackles with the creation of this platform: that of the confidentiality of patient data, and the absence, to date, of mechanisms to standardize data transfer at European and international level.
The IHU ICAN has been addressing the issue of data for several months now, notably through the implementation of major research projects, such as Maestria, and relies on complete and secure management of the entire data “chain”, by structuring data collection thanks to a person dedicated to data governance, 2 data managers to collect, extract and classify the data collected and a data scientist to analyze them. The expertise of the ICAN Intelligence and Omics platform is backed by the legal department to answer regulatory questions.
The IHU ICAN is therefore positioned as a major international player capable of generating massive health data and, above all, of analyzing it and extracting the necessary knowledge in order to gain a better understanding of biology and thus contribute to improving public health.
The ICAN Intelligence and Omics (I/O) platform thus offers a service adapted for both academic and industrial research.
New Scientific Advisory Board for the IHU
New Scientific Advisory Board for the IHU ICAN
At the December 16, 2021 Board of Directors meeting, ICAN announced the composition of its new Scientific Advisory Board . ICAN has a prestigious SAB (Scientific Advisory Board) which has grown from 4 to 5 members in order to strengthen international scientific collaborations and to cover the main fields of interest of the IHU.
Composed of personalities recognized by the international scientific community in the field of cardiometabolism and nutrition, the SAB participates in the definition of ICAN’s scientific strategy and evaluates its scientific performance. It therefore plays a very important role in the scientific trajectory of ICAN.
Members of the SAB:
New Members
Scientific Director of the CHUS Research Centre
Professor at the Canadian Research Chair in Molecular Imaging of Diabetes
Department of Medicine
Sherbrooke University – Canada
Director of the German Diabetes Center (DDZ), Professor of Endocrinology and Metabolic Diseases – Heinrich Heine University Düsseldorf
Director of the Division of Endocrinology and Diabetology at the University Hospital Düsseldorf
Germany
Professor of Medicine and Head of Experimental Cardiology at the University of Leuven
Editor-in-Chief of Cardiovascular Research since January 2013
Belgium
Renewed members
Director of the Institute of Clinical Chemistry, Presidency POCT Commission, Medical Diagnostic Department
Co-Director, University Centre for Laboratory Medicine and Pathology – UZL
Swiss
Professor Rozemarijn Vliegenthart
Radiologist and professor of cardiothoracic imaging at the University Medical Center of Groningen
The Netherlands.
Laurence Comte-Arassus joins the IHU-ICAN Board of Directors
Laurence Comte-Arassus joins the IHU-ICAN Board of Directors
Laurence Comte-Arassus, member of the board of directors and of the office of Snitem (National union of the medical technology industry) will participate this Thursday, June 24 for the first time in the board of directors of the IHU-ICAN (Institut hospitalo -academic of cardiometabolism and nutrition) as a qualified personality from the economic world.
Laurence Comte-Arassus was appointed to the IHU-ICAN Board of Directors last March. His appointment by the current board of directors reflects IHU-ICAN’s desire to strengthen its links with medical device companies. This university hospital institute, located in the heart of the Pitié-Salpêtrière hospital, relies on the medical and scientific excellence, in the field of cardiometabolic diseases, of the doctors and researchers of the AP-HP, the ‘Inserm and Sorbonne University. It is thus continuing its in-depth transformation to develop more public/private collaborations with a view to accelerating innovations for the benefit of patients suffering from cardiometabolic and nutritional pathologies.
The perfect knowledge of the medical device industry acquired during a remarkable professional career and her role within the Snitem will allow Laurence Comte-Arassus to bring a new dimension to the construction of the partnership policy of the IHU- I CAN.
Course of Laurence Comte-Arassus
Laurence Comte-Arassus joined GE Healthcare in February 2021, as General Manager of the France, Belgium, Luxembourg and French-speaking Africa (FBFA) zone after 26 years of experience in the technology and medical sector. She previously held the position of President of Medtronic France. She is also a member of several health think tanks.
About Snitem
Created in 1987, the National Union of the Medical Technology Industry (Snitem) brings together players in the medical technology and device industry, including companies involved in digital health. It federates more than 525 French or international companies, most of which are of the size of SMEs or ETIs. The Snitem is thus the first organization in France representing companies in this sector of activity and the privileged and referent interlocutor of the Public Authorities.
